ArticleJournal of inflammation research2026
Integrated Multi-Omics Analyses Identify TYMP as a Candidate Protective Immunoregulatory Marker in CD4⁺ T Cells During Sepsis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cellular heterogeneity in sepsis complicates the identification of cell-specific therapeutic targets. We aimed to identify genetically supported candidate immunogenetic regulators associated with sepsis through integrative multi-omics analyses. Methods: We conducted an integrative observational multi-omics study combining single-cell expression quantitative trait locus-based Mendelian randomization (sc-eQTL MR), bulk transcriptomic survival analysis, genetic colocalization, single-cell RNA sequencing (scRNA-seq), and a prospective observational clinical cohort. Publicly available summary-level or de-identified datasets were analyzed, including FinnGen sepsis GWAS data (GWAS ID: finn-b-O15_PUERP_SEPSIS), OneK1K sc-eQTL data, bulk transcriptomic data (GSE65682), and scRNA-seq datasets (GSE167363 and GSE151263). For prospective validation, 30 consecutive adult patients admitted to the intensive care unit who fulfilled the Sepsis-3 criteria were enrolled at the Affiliated Jiangyin Hospital of Nantong University between January 2026 and April 2026. Peripheral blood was collected within 24 hours after fulfillment of the Sepsis-3 criteria. TYMP concentrations in plasma were quantified using ELISA. Results: TYMP showed a nominal inverse association with sepsis susceptibility in CD4 effector memory/TEMRA cells (OR = 0.644, P = 0.008) in the exploratory MR screening, while genetic colocalization suggested a shared genetic signal with sepsis susceptibility (PPH4 = 0.78). In an independent cohort of 30 patients with sepsis, plasma TYMP levels were significantly elevated in survivors than in non-survivors (124.9 ± 20.7 vs 109.6 ± 15.1 pg/mL, P = 0.033). TYMP exhibited prognostic value for 28-day mortality (AUC = 0.701, P = 0.042), and elevated TYMP expression was associated with improved survival (HR = 0.259, P = 0.029). Single-cell and pseudotime analyses associated TYMP-expressing CD4⁺T cells with immunoregulatory transcriptional programs involving hypoxia and TGFB1 signaling. Pseudotime analysis demonstrated dynamic transcriptional reprogramming toward an immunoregulatory state. Conclusion: Integrated genetic, transcriptomic, single-cell, and clinical analyses nominate TYMP as a genetically supported candidate protective immunoregulatory marker associated with CD4⁺T cells in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.